2025
Genetic and oncogenic features of RASGRF fusions
Das S, Lenchner D, Jaeger E, Hunihan L, DeSantis D, Fragkogianni S, Ronski K, Wilson F. Genetic and oncogenic features of RASGRF fusions. Npj Precision Oncology 2025, 9: 224. PMID: 40615519, PMCID: PMC12227644, DOI: 10.1038/s41698-025-01017-1.Peer-Reviewed Original ResearchGuanine exchange factorDH domainRNA-seq dataNon-small cell lung carcinomaExchange factorGenetic heterogeneityMembrane localizationCellular transformationChimeric proteinDiverse human malignanciesPH1 domainRas activationMAPK pathway inhibitionTransforming activityOncogenic featuresSubsets of cancersRasGRFOncogenic mechanismsFunctional assaysTargeted therapeutic strategiesRasGRF1Human malignanciesStructural diversityOncogenic fusionsPathway inhibition
2021
Osimertinib in EGFR-Mutant Non-Small Cell Lung Carcinoma: Clinical Activity and Mechanisms of Resistance
Talsania A, Zhang J, Wilson F. Osimertinib in EGFR-Mutant Non-Small Cell Lung Carcinoma: Clinical Activity and Mechanisms of Resistance. Current Cancer Research 2021, 65-73. DOI: 10.1007/978-3-030-74028-3_4.ChaptersNon-small cell lung carcinomaEGFR-mutant non-small cell lung carcinomaEpidermal growth factor receptorCell lung carcinomaLung carcinomaSmall cell lung carcinomaEGFR-Mutant NonMajor therapeutic challengeCare of patientsPotential therapeutic strategyConstitutive EGFR activationThird-generation EGFR inhibitorsUpregulation of pathwaysGrowth factor receptorResistance mechanismsAdjuvant settingTherapeutic challengeMechanisms of resistanceClinical activityTherapeutic strategiesClinical developmentSmall molecule inhibitorsEGFR inhibitorsFactor receptorEGFR activation
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply